Today: 19 January 2026
Subscribe
Browse Category

Clinical Trials News 8 December 2025 - 23 December 2025

SELLAS Life Sciences (SLS) Stock Update: ASH 2025 Data, REGAL Trial Countdown, Analyst Targets, and Key Risks (Dec. 23, 2025)

SELLAS Life Sciences (SLS) Stock Update: ASH 2025 Data, REGAL Trial Countdown, Analyst Targets, and Key Risks (Dec. 23, 2025)

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) is closing out 2025 on a familiar biotech cocktail: fresh clinical data, a major late-stage catalyst approaching, and market activity that suggests traders are positioning for volatility. As of 12:22 UTC on Tuesday, Dec. 23, 2025, SLS stock traded around $2.64, according to market data. In the prior session, the stock closed around…
23 December 2025
····
Zenas BioPharma (ZBIO) Stock Hits a Record High on Dec. 22, 2025 as INDIGO Phase 3 Catalyst Nears — Latest News, Analyst Forecasts, and What’s Next

Zenas BioPharma (ZBIO) Stock Hits a Record High on Dec. 22, 2025 as INDIGO Phase 3 Catalyst Nears — Latest News, Analyst Forecasts, and What’s Next

Zenas BioPharma, Inc. (NASDAQ: ZBIO) is having one of those classic biotech days where the market starts acting like it can see the future. On Monday, December 22, 2025, ZBIO surged roughly 14% and traded around $41.23 by early afternoon Eastern time—after touching a fresh all-time high near $41.67, according to multiple market data reports. MarketBeat The timing isn’t subtle:…
22 December 2025
····
Recursion Pharmaceuticals Stock (RXRX) News and Forecasts for Dec. 20, 2025: TUPELO Trial Data, JPMorgan Upgrade, and What Comes Next

Recursion Pharmaceuticals Stock (RXRX) News and Forecasts for Dec. 20, 2025: TUPELO Trial Data, JPMorgan Upgrade, and What Comes Next

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) heads into the weekend of December 20, 2025 with investors still digesting a fast-moving sequence of catalysts: fresh clinical data for its lead program REC-4881, a notable JPMorgan upgrade, and a burst of unusually heavy trading volume that has kept the stock in the spotlight. Because U.S. markets are closed on Saturday, the most recent…
20 December 2025
····
Edgewise Therapeutics Stock (EWTX) Today: Why Shares Fell on Dec. 18, 2025, Plus Latest News, Analyst Forecasts, and Key Clinical Catalysts

Edgewise Therapeutics Stock (EWTX) Today: Why Shares Fell on Dec. 18, 2025, Plus Latest News, Analyst Forecasts, and Key Clinical Catalysts

December 18, 2025 — Edgewise Therapeutics, Inc. (NASDAQ: EWTX) saw its shares slide sharply in Thursday trading, a reminder that clinical-stage biotech stocks can move fast even when there’s no single headline screaming for attention. EWTX finished the session around $20.35, down roughly 8.8% from the prior close, after trading between about $20.33 and $22.81. StockAnalysis That drop matters because…
18 December 2025
····
Recursion Pharmaceuticals (RXRX) Stock News & Forecast (Dec. 18, 2025): JPMorgan Upgrade, REC-4881 Trial Momentum, and What Analysts See Next

Recursion Pharmaceuticals (RXRX) Stock News & Forecast (Dec. 18, 2025): JPMorgan Upgrade, REC-4881 Trial Momentum, and What Analysts See Next

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) is back in the market’s spotlight on December 18, 2025, after a sharp move higher driven by fresh Wall Street optimism and a growing pile of real-world “proof points” for the company’s AI-driven drug discovery thesis. The setup is classic biotech: a clinical readout starts the spark, an analyst upgrade adds oxygen, and the stock…
18 December 2025
····
Processa Pharmaceuticals (PCSA) Stock: Phase 2 Breast Cancer Update, 1-for-25 Reverse Split, and What Wall Street Is Watching on Dec. 18, 2025

Processa Pharmaceuticals (PCSA) Stock: Phase 2 Breast Cancer Update, 1-for-25 Reverse Split, and What Wall Street Is Watching on Dec. 18, 2025

December 18, 2025 — Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) is back on traders’ radar after the company reported fresh clinical observations from its Phase 2 breast cancer program and implemented another reverse stock split to consolidate shares. The result: a whiplash week for the stock, a surge in attention, and a new set of near-term catalysts that now matter more…
18 December 2025
···
Immunome (IMNM) Stock Surges After Positive Phase 3 Varegacestat Data: Latest News, Analyst Forecasts, and What Comes Next (Dec. 15, 2025)

Immunome (IMNM) Stock Surges After Positive Phase 3 Varegacestat Data: Latest News, Analyst Forecasts, and What Comes Next (Dec. 15, 2025)

December 15, 2025 — Immunome, Inc. (NASDAQ: IMNM) is having the kind of biotech day that traders circle in red ink: a major clinical trial win, a sharp move in the share price, and a fast-rising debate over what “best-in-class” might be worth if regulators agree. The catalyst is Immunome’s positive topline Phase 3 RINGSIDE results for varegacestat (formerly AL102)…
15 December 2025
····
Rezolute (RZLT) Stock Update Dec. 12, 2025: Phase 3 sunRIZE Miss Sparks Selloff, Analysts Reset Targets, and 2026 Catalysts

Rezolute (RZLT) Stock Update Dec. 12, 2025: Phase 3 sunRIZE Miss Sparks Selloff, Analysts Reset Targets, and 2026 Catalysts

Rezolute, Inc. (NASDAQ: RZLT) is one of the most closely watched biotech movers heading into the Dec. 12, 2025 session after a pivotal clinical trial miss triggered a historic repricing of the stock. As of the latest available trading update on Friday, December 12, 2025, Rezolute shares are trading around $1.40, down roughly $9.55 versus the prior close—about an 87%…
12 December 2025
···
Belite Bio (NASDAQ: BLTE) Stock: DRAGON Trial Breakthrough, $350 Million Offering and Outlook After a 130% Rally

Belite Bio (NASDAQ: BLTE) Stock: DRAGON Trial Breakthrough, $350 Million Offering and Outlook After a 130% Rally

Belite Bio, Inc. (NASDAQ: BLTE) has turned into one of 2025’s most closely watched biotech stories. On the back of a pivotal Phase 3 win in Stargardt disease and a large equity raise, the small-cap ophthalmology specialist has seen its share price more than double this year and its market value climb into the multi‑billion‑dollar range. BioPharma Dive As of…
11 December 2025
····
Biodexa Pharmaceuticals (NASDAQ: BDRX) Stock on December 10, 2025: Violent Rally, Phase 3 FAP Progress and What 2026 Might Hold

Biodexa Pharmaceuticals (NASDAQ: BDRX) Stock on December 10, 2025: Violent Rally, Phase 3 FAP Progress and What 2026 Might Hold

Biodexa Pharmaceuticals plc (NASDAQ: BDRX) has turned into one of the most volatile biotech tickers of late 2025. After a sharp multi‑day surge driven by retail trading interest and momentum headlines, the stock has whipsawed back down, even as the company advances a pivotal Phase 3 trial in a rare inherited cancer syndrome and lines up multiple new financing options.…
10 December 2025
····
Exicure (XCUR) Stock Soars on Burixafor Phase 2 Data: What December 2025 Investors Need to Know

Exicure (XCUR) Stock Soars on Burixafor Phase 2 Data: What December 2025 Investors Need to Know

As of December 9, 2025 Exicure, Inc. (NASDAQ: XCUR) has suddenly moved from obscure micro‑cap to front‑page biotech story. After the company reported positive topline Phase 2 data for its lead drug candidate burixafor in multiple myeloma at the 2025 ASH Annual Meeting on December 8, the stock exploded higher in after‑hours and pre‑market trading. Exicure Below is a comprehensive…
9 December 2025
····
Arrowhead Pharmaceuticals (ARWR) Soars to Fresh Highs on Alzheimer’s Trial and FDA Breakthrough Wins

Arrowhead Pharmaceuticals (ARWR) Soars to Fresh Highs on Alzheimer’s Trial and FDA Breakthrough Wins

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is finishing 2025 with the kind of momentum small-molecule biotechs daydream about. On 8 December 2025, the RNA interference (RNAi) specialist climbed to a new 52‑week high near $69 per share after the company announced it had dosed the first subjects in its Alzheimer’s disease trial ARO‑MAPT and highlighted a string of recent FDA victories…
8 December 2025
···
1 2 3 4 5 6 … 8

Stock Market Today

  • Adecco Group Shares Dip Amid Mixed Returns, Valuation Suggests Undervaluation
    January 19, 2026, 12:28 PM EST. Adecco Group (SWX:ADEN) shares declined 2.14% recently, trading at CHF22.86 after a mixed performance over the past year and longer-term negative returns. The stock shows a 1-year total shareholder return of 9.38%, contrasting with negative returns over three and five years. Analysts place Adecco's fair value at CHF26.96, implying undervaluation based on expected earnings growth and margin improvements, backed by strategic focus on specialized sectors like IT, life sciences, and aerospace. Key risks include potential disruption from automation, AI, and digital platform competition in staffing services. Investors should weigh growth prospects against these risks when considering Adecco's stock, which remains under pressure amid market reassessment.
Go toTop